Year-end report October - December 2022
Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Year-end report October – December 2022. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
“As we close the books for the financial year of 2022, we can look back on a pivotal year characterized by intensive strategic work. Since the IPO in 2020, Curasight has presented positive results from several investigator-initiated studies with uTRACE®. With an updated clinical strategy in 2022 we are now pursuing several promising indications such as prostate cancer, head- and neck cancer, neuroendocrine tumours, and brain cancer for uTRACE®.
The new strategy enables Curasight to advance its position as a theranostic company and accelerate its development of the theranostic solutions. Ultimately, we aim to provide more accurate diagnosis via intelligent cancer imaging (uTRACE®) and targeted treatments (uTREAT®), creating additional treatment options and potentially more gentle and efficient treatments of various cancers.
Last but not least Curasight is building its drug development function to meet the regulatory demands of running a late stage clinical development company. This focus involves our first discussions with the US Food and Drug Administration (FDA) about our clinical programs on uTRACE® and continuing the clinical Investigation of uTRACE® in the prostate cancer indication. In summary, all the hard work in 2022 sets the foundation for a rich news flow during 2023 that will fuel Curasights value inflection points. Thank you for sharing our mission to improve the lives of millions of people with cancer.”
Q4 (2022-10-01 – 2022-12-31)
• Net sales amounted to 0 (0) DKK
• Operating profit/loss amounted to -7,065,538 (-6,696,199) DKK
• Profit/loss before taxes amounted to -7,095,175 (-6,860,301) DKK
• Profit/loss for the period amounted to -6,810,359 (-6,693,691) DKK
• Total assets amounted to 59,667,946 (77,915,451) DKK
• Equity ratio amounted to 96,5 (97,4) %.
• Earnings per share amounted to -0.34 (-0.33) DKK
Q1-Q4 (2022-01-01 – 2022-12-31)
• Net sales amounted to 0 (0) DKK
• Operating profit/loss amounted to -18,962,317 (-11,401,890) DKK
• Profit/loss before taxes amounted to -19,488,453 (-11,781,790) DKK
• Profit/loss for the year amounted to -18,349,187 (-11,115,350) DKK
• Total assets amounted to 59,667,946 (77,915,451) DKK
• Equity ratio amounted to 96,5 (97,4) %.
• Earnings per share amounted to -0.92 (-0.56) DKK
Highlights during the fourth quarter
- October 13: Curasight announced that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT®) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.
- November 21: Ulrich Krasilnikoff and Andreas Kjær presented the company and the strategy at SEB Healthcare Seminar 2022.
- November 28: Ulrich Krasilnikoff and Andreas Kjær presented the company and the Q3 2022report at HC Andersen Capital.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.